AHA Scientific Sessions 2023 Late-Breaking Science Coverage

Published: 30 October 2023

  • Views:

    Views Icon 2173
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Stay up-to-date with the latest data in cardiovascular science with the help of renowned experts and emerging voices who offer concise summaries, in-depth discussions, and critical reviews to keep you informed.

 

In their regular View from the Thoraxcenter series, Prof Van Mieghem and Dr Daemen provide valuable insights into the most anticipated trials of AHA 23. With their keen awareness of cardiovascular innovation, they offer concise perspectives on late-breaking data.

 

Dr Harriette Van Spall returns with her Late-breaker Discussion series featuring ground-breaking research presented at Scientific Sessions. Join her and lead investigators as they discuss methodology, results, and impact on patient care.

 

Watch our Expert interviews for late-breaking science methodology, results and implications for practice and research in under 10 minutes.

 

Delve into the personal motivations of some of the investigators, and gain valuable insights and advice for early career researchers in our Behind the Heart series. These short videos offer an opportunity to look beyond scientific achievements and connect on a more personal level.

More from this programme

Part 1

View from the Thoraxcenter

In their regular View from the Thoraxcenter series, Prof Van Mieghem and Dr Daemen provide valuable insights into the most anticipated trials of AHA 23. 

Part 2

Late-Breaker Discussions with Harriette Van Spall

Dr Harriette Van Spall, recipient of 2022's AHA Dr. Nanette K. Wenger Award, returns with her Late-breaker Discussion series featuring ground-breaking research presented at Scientific Sessions. Join her and lead investigators as they discuss methodology, results, and impact on patient care.

About the episode

AHA 23 - Investigator, Dr Mandeep R Mehra (Brigham and Women's Hospital and Harvard Medical School, US) is joined by Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) to discuss the ARIES HM3 trial.

ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were treated with two different antithrombotic regimens. One treatment group received a Vitamin K antagonist, whereas another group received a vitamin K antagonist with placebo.

The non-inferiority endpoint for this study will be met if the placebo arm is non-inferior to the aspirin arm in the composite of survival free of any non-surgical major hemocompatibility-related adverse event at one-year post-implant.

Findings indicated that the omission of aspirin from an antithrombotic regimen including a VKA in advanced heart failure patients with a left ventricular assist device (LVAD) demonstrated non-inferiority when compared to a regimen that included aspirin. This approach was also associated with a reduction in bleeding events without an increased risk of thromboembolic events. Notably, the study observed a substantial 47% decrease in the number of hospitalization days, accompanied by a 41% reduction in the cost of managing bleeding events. Researchers estimated that for every 100 patients receiving the study LVAD, the strategy of avoiding aspirin therapy prevented approximately 14.5 major bleeding events during the first year.

Recorded Remotely from Boston, MA, 2023.

Faculty Biographies

Mandeep Mehra

Mandeep Mehra

Personal History

Dr Mandeep R Mehra was born on December 3rd, 1967 in Delhi, India— the historic day Christiaan Barnard carried out the first human heart transplant.7 One of the country’s leading cardiologists in advanced heart failure and cardiac transplantation, he is a Professor of Medicine at Harvard Medical School and the Medical Director of the Brigham and Women’s Hospital (BWH) Heart and Vascular Center.5

Dr. Mehra says heart center cardiologists and surgeons practice a form of medicine that mirrors the vision of the future, which is cardiac care that is predictive, personalized, preemptive and participatory. His time at the University of Maryland Medical Center was marked by compassionate personalised care and a special emphasis on cardiac care for the whole person.3

Academic History

An alumnus of the 1983 batch, Dr Mehra received his medical degree from Mahatma…

View full profile
Harriette Van Spall

Harriette Van Spall

Associate Professor of Medicine, Director of E-Health and Virtual Care

Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.

She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.

Dr Van Spall is an Editorial Board…

View full profile

Comments

You must be to comment. If you are not registered, you can register here.